Algert Global LLC Makes New $844,000 Investment in Repligen Co. (NASDAQ:RGEN)

Algert Global LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,865 shares of the biotechnology company's stock, valued at approximately $844,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC boosted its position in shares of Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after acquiring an additional 90 shares during the last quarter. Clark & Stuart Inc purchased a new position in shares of Repligen during the fourth quarter valued at approximately $202,000. Moody National Bank Trust Division grew its stake in Repligen by 10.2% in the fourth quarter. Moody National Bank Trust Division now owns 1,591 shares of the biotechnology company's stock worth $229,000 after purchasing an additional 147 shares during the period. Park Avenue Securities LLC grew its stake in Repligen by 24.8% in the fourth quarter. Park Avenue Securities LLC now owns 3,901 shares of the biotechnology company's stock worth $561,000 after purchasing an additional 776 shares during the period. Finally, Integrated Investment Consultants LLC boosted its holdings in Repligen by 6.0% in the fourth quarter. Integrated Investment Consultants LLC now owns 2,360 shares of the biotechnology company's stock worth $340,000 after acquiring an additional 134 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Margaret Pax bought 250 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of recent research reports. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Evercore ISI initiated coverage on Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target for the company. Canaccord Genuity Group cut their price target on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. Finally, JPMorgan Chase & Co. dropped their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $173.25.

Repligen Trading Up 1.3%

RGEN stock traded up $1.62 during midday trading on Friday, hitting $124.88. 643,976 shares of the company's stock were exchanged, compared to its average volume of 730,859. The business has a 50-day simple moving average of $133.15 and a two-hundred day simple moving average of $145.12. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.01 billion, a PE ratio of -244.86, a P/E/G ratio of 4.54 and a beta of 1.21. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same period in the previous year, the firm posted $0.28 earnings per share. The company's revenue was up 10.4% on a year-over-year basis. On average, sell-side analysts predict that Repligen Co. will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.